Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer

On May 12, 2022 Veracyte, Inc. (Nasdaq: VCYT) reported that an updated clinical guideline from the American Urological Association (AUA) and the American Society for Radiation Oncology (ASTRO) includes a new statement that is favorable for genomic testing, including the Decipher Prostate genomic classifier, to help guide care for men with localized prostate cancer (Press release, Veracyte, MAY 12, 2022, View Source [SID1234614426]). The guideline authors specifically cite extensive evidence, including from multiple phase 3 randomized clinical trials, which have previously demonstrated that the Decipher Prostate genomic risk score is strongly associated with important prostate cancer-specific and oncologic outcomes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The updated guideline, which appears on the AUA website and online in The Journal of Urology, states that clinicians may selectively use tissue-based genomic biomarkers when added risk-stratification may alter clinical decision-making. The guideline specifically says, "Of note, accumulating evidence has indicated that GC [genomic classifier] scores, specifically Decipher, derived from biopsy specimens do correlate with cancer outcomes."

"We are extremely pleased that this updated guideline recognizes the important role that genomic testing can play in determining treatment approaches for men with localized prostate cancer," said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. "Notably, the guideline authors point to extensive data from multicenter, prospectively collected, phase 3 randomized trials that demonstrate association of Decipher Prostate test results with risk of distant metastasis and prostate-cancer-specific mortality. These include studies of patients on active surveillance to men with high-risk prostate cancer. We believe our test can give physicians and patients the clarity and confidence they need to select appropriate treatment approaches."

Veracyte will be sharing information about the Decipher Prostate genomic test at Booth #1563 of the 2022 AUA Annual Meeting, which is taking place May 13-16 in New Orleans.

About Decipher Prostate

The Decipher Prostate genomic classifier is a 22-gene, whole-transcriptome-developed genomic test designed to help inform treatment decisions for men with localized prostate cancer at initial diagnosis and after surgical removal of the prostate. The test reports the Decipher Score, which prognosticates a patient’s risk of metastasis within five years and provides risk estimates of prostate cancer-specific outcomes. Decipher Prostate can help guide physicians to better select the appropriate therapy for a specific patient, which in turn can result in improved patient outcomes.